Get started
Author

Roberto Serna‐Blasco

Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer
2023 · Mariano Provencio, Ernest Nadal, et al. · New England Journal of Medicine · 559
PDF
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
2022 · Mariano Provencio, Roberto Serna-Blasco, et al. · Journal of Clinical Oncology · 386
Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis
2022 · Estela Sánchez-Herrero, Roberto Serna-Blasco, et al. · Frontiers in Oncology · 211
PDF
Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial
2024 · Mariano Provencio, Ernest Nadal, et al. · The Lancet Oncology · 122
PDF
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
2022 · Marta Casarrubios, Mariano Provencio, et al. · Journal for ImmunoTherapy of Cancer · 75
Vitamin C activates pyruvate dehydrogenase (PDH) targeting the mitochondrial tricarboxylic acid (TCA) cycle in hypoxic KRAS mutant colon cancer
2021 · Aiora Cenigaonandia-Campillo, Roberto Serna-Blasco, et al. · Theranostics · 65
Targeting the RAS-dependent chemoresistance: The Warburg connection
2018 · Roberto Serna-Blasco, Marta Sanz-Álvarez, et al. · Seminars in Cancer Biology · 56
Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial
2022 · Mariano Provencio, Ana Laura Ortega, et al. · JAMA Oncology · 55
PDF
Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor–positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment
2021 · Mariano Provencio, Roberto Serna-Blasco, et al. · European Journal of Cancer · 36
NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment
2021 · Estela Sánchez‐Herrero, Roberto Serna‐Blasco, et al. · Molecular Oncology · 29
PDF
ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib
2020 · Atocha Romero, Roberto Serna-Blasco, et al. · Translational Lung Cancer Research · 28
PDF
Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection
2021 · Mariano Provencio, Margarita Majem, et al. · Lung Cancer · 27
Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation
2020 · Miguel Barquín, Virginia Calvo, et al. · Cancer Epidemiology · 26
Use of Liquid Biopsy in the Care of Patients with Non-Small Cell Lung Cancer
2021 · Atocha Romero, Roberto Serna-Blasco, et al. · Current Treatment Options in Oncology · 20
Cancer as an infective disease: the role of EVs in tumorigenesis
2022 · Lucia Robado de Lope, Estela Sánchez‐Herrero, et al. · Molecular Oncology · 13
PDF
ALK-Fusion Transcripts Can Be Detected in Extracellular Vesicles (EVs) from Nonsmall Cell Lung Cancer Cell Lines and Patient Plasma: Toward EV-Based Noninvasive Testing
2022 · Estela Sánchez-Herrero, Carmen Campos-Silva, et al. · Clinical Chemistry · 13
PDF
KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor
2021 · R. Serna-Blasco, E. Sánchez-Herrero, et al. · ESMO Open · 13
PDF
Analysis of Potential Alterations Affecting SETBP1 as a Novel Contributing Mechanism to Inhibit PP2A in Colorectal Cancer Patients
2018 · Blanca Torrejón, Ion Cristóbal, et al. · World Journal of Surgery · 13
Comprehensive molecular profiling of advanced NSCLC using NGS: Prevalence of druggable mutations and clinical trial opportunities in the ATLAS study
2025 · Roberto Serna Blasco*, Pilar Mediavilla Medel*, et al. · Lung Cancer · 12
BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC
2024 · Mariano Provencio, Lucía Robado de Lope, et al. · Lung Cancer · 10
PDF
Targeting KRAS Mutant CMS3 Subtype by Metabolic Inhibitors
2018 · Oscar Aguilera, Roberto Serna-Blasco · Advances in experimental medicine and biology · 10
KRAS Mutation Status in Non-Small Cell Lung Cancer Distribution Across Occupational Categories
2025 · Roberto Serna-Blasco, Karla Medina, et al. · CHEST Journal · 3
210P: Prognostic Value of minimal residual disease in the NADIM II trial
2025 · R. Serna-Blasco, E. Nadal, et al. · Journal of Thoracic Oncology · 3
PDF
Abstract 6684: Impact of fecal microbiome on the efficacy of neoadjuvant chemo-immunotherapy and colitis adverse events: Findings from the NADIM II Trial
2024 · Roberto Serna-Blasco, Alejandro Rodriguez Festa, et al. · Cancer Research · 3
R-Score: A New Parameter to Assess the Quality of Variants’ Calls Assessed by NGS Using Liquid Biopsies
2021 · Roberto Serna-Blasco, Estela Sánchez-Herrero, et al. · Biology · 3
PDF
Works count: 44
Citation count: 1,794
H-index: 14
I10-index: 21
Year
Topic
Type